The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies |
| |
Authors: | Jun-Xia Cao Wei-Jian Gao Jia You Li-Hua Wu Jin-Long Liu Zheng-Xu Wang |
| |
Affiliation: | Biotherapy Center, The Seventh Medical Center of PLA General Hospital, Beijing, China |
| |
Abstract: | Immunotherapy with chimeric antigen receptor T (CAR-T) cells has proved remarkably effective in recently published clinical trials. In this meta-analysis, we performed a systematic review in terms of the clinical response treated with CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and lymphomas patients. Thirty-eight published clinical studies including 665 patients were eligible for response rate (RR) evaluation. The overall pooled RR of CD19-CAR-T cells was 72% (95% confidence interval: 62–77%). The various clinical parameters were analyzed. RR was 81% in ALL, 68% in lymphoma and 70% in CLL. RR in patients who received interleukin (IL)-2 was 70%, whereas in those who did not receive IL-2, it was 74%. RR was 75% with lymphodepletion and 56% without lymphodepletion. RR with autologous cells was 76% and 57% with allogeneic cells. In conclusion, this meta-analysis showed a high clinical RR of CD19-CAR-T cell–based immunotherapy in patients with refractory B-cell malignancies. |
| |
Keywords: | CAR-T acute lymphocytic leukemia chronic lymphocytic leukemia lymphomas meta-analysis |
本文献已被 ScienceDirect 等数据库收录! |
|